Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc is demonstrating increasing confidence in the efficacy and safety of its lead product candidate, KYV-101, positioned for myasthenia gravis (MG), with a raised probability of approval reflecting improved clinical outcomes. The company is also witnessing positive early signals in treating refractory rheumatoid arthritis (RA) and multiple sclerosis (MS), indicating a broadening applicability of its CAR T-cell therapies beyond traditional treatment lines. This favorable data trend supports a positive long-term outlook for KYV-101, bolstering investor confidence and prompting revisions in price targets.

Bears say

Kyverna Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to concerns regarding the efficacy and durability of its lead product candidate, KYV-101. Despite initial positive responses in clinical trials, the potential lack of durable responses for patients, particularly in lupus nephritis (LN) and myasthenia gravis (MG), raises questions about the long-term viability of the treatment. Additionally, there is apprehension regarding the ability to generate positive data for KYV-101 in specific indications, as well as risks associated with potential long-term dilution, which could affect shareholder value.

KYTX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 3 analysts, KYTX has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.